GOLDSMITH MARK A sold $1.6M of RVMD
GOLDSMITH MARK A (See Remarks) sold 10,020 shares of Revolution Medicines, Inc. (RVMD) at $156.12 ($1.56M total) on 2026-06-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price ($156.1188/share), and post-transaction holdings (267,330 shares), which can influence short-term sentiment but does not provide new company performance or guidance.
Market read
A $1.56M insider sale under a 10b5-1 plan is a concrete datapoint, but it is typically not a standalone catalyst for repricing.
What to watch
Traders may over-weight insider sales; the more actionable signal would be whether subsequent filings show repeated selling or changes in trading plans.
Background
This is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc. (RVMD).
Ticker impact
Revolution Medicines insider Mark A. Goldsmith sold 10,020 shares in an open-market transaction for about $1.56M, per Form 4 filed June 18.
Likely limited/short-lived impact; watch for follow-through only if additional insider selling accelerates.
Form 4 provides a concrete, time-stamped datapoint (size, price, post-sale holdings) but the presence of a 10b5-1 plan reduces interpretability as a new bearish signal.
Market effects
Minimal; single-company insider sale without clinical/regulatory updates does not reset sector expectations.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a change in fundamentals.
Key entities
- issuerRevolution Medicines, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderGOLDSMITH MARK A
Officer/director who sold 10,020 shares in an open-market transaction.
